Alkermes

Drug rejections rise as Covid-19 bites
EP Vantage
Wed, 11/18/20 - 01:20 pm
COVID-19
drug approvals
Alkermes
ALKS 3831
pandemic
regulatory inspections
Alkermes is handed a CRL for ‘3831, marking another setback on the R&D front
Endpoints
Tue, 11/17/20 - 10:48 am
Alkermes
ALKS-3831
FDA
CRL
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
Xconomy
Sat, 10/10/20 - 11:36 pm
Alkermes
FDA
advisory panels
ALKS 3831
schizophrenia
bipolar disorder
FDA Raises Concern Over Opioid Abuse Related to Alkermes' Schizophrenia Drug
BioSpace
Thu, 10/8/20 - 11:21 pm
Alkermes
FDA
schizophrenia
opioids
ALKS 3831
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
Wed, 09/30/20 - 10:45 am
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Esmo 2020 – can Alkermes succeed where Nektar failed?
EP Vantage
Wed, 09/23/20 - 10:33 am
Alkermes
ESMO
ALKS 4230
melanoma
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
Fierce Biotech
Fri, 09/18/20 - 11:09 am
Alkermes
immuno-oncology
ESMO
ALKS 4230
Keytruda
Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions
Fierce Biotech
Fri, 08/21/20 - 11:36 pm
Alkermes
schizophrenia
bipolar disorder
FDA
ALKS 3831
Top Biopharma M&As in 2019
BioSpace
Fri, 01/3/20 - 10:06 am
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
FDA slaps down Alkermes for misleading Vivitrol ads — don't forget vulnerability to opioid overdose
Endpoints
Wed, 12/11/19 - 10:24 pm
Alkermes
drug ads
Vivitrol
Alkermes To Acquire Rodin Therapeutics
NASDAQ
Mon, 11/18/19 - 09:58 am
Alkermes
Rodin Therapeutics
M&A
CNS
Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?
Endpoints
Wed, 10/30/19 - 10:13 am
Biogen
Alkermes
FDA
multiple sclerosis
MS
Vumerity
Alkermes to lay off 160 in cost-cutting restructure
Biopharma Dive
Wed, 10/23/19 - 02:57 pm
Alkermes
restructuring
layoffs
The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera
Endpoints
Tue, 07/30/19 - 11:29 am
Biogen
Alkermes
MS
multiple sclerosis
Vumerity
clinical trials
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
Sun, 07/28/19 - 11:48 pm
biotech
earnings
Immunic
Alkermes
Conatus
Aevi Genomic
Tricida
Curis
Ultragenyx
Leap Therapeutics
Cidara Therapeutics
Akcea
Spark Therapeutics
Eli Lilly
AnaptysBio
clinical trials
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Thu, 05/30/19 - 09:42 am
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Here's Why Shares of Alkermes Sank Today
Motley Fool
Thu, 04/25/19 - 06:50 pm
Alkermes
earnings
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
CP WIre
Mon, 02/25/19 - 12:24 pm
Alkermes
Biogen
diroximel fumarate
MS
multiple sclerosis
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
Mon, 02/25/19 - 10:16 am
Alkermes
Biogen
diroximel fumarate
Alkermes Breaks $1 Billion
Motley Fool
Tue, 02/19/19 - 12:18 pm
Alkermes
earnings

Pages